Our clinical programs are leading the field
Explore the scientific evidence supporting GRAIL’s multi-cancer early detection approach, including peer-reviewed publications and presentations at leading medical congresses. Together, these data highlight test performance, clinical utility, and progress toward transforming cancer screening.
Foundational data
Case control study
Annals of Oncology
Read Full Article
PATHFINDER 2
Prospective screening studies
The Lancet
Read Full Article
Randomized control study (design)
Cancers, MDPI
Read Manuscript
Prospective real-world study
Nature Communications
Read Full Article
Featured evidence
European Society for Medical Oncology (ESMO) 2025
Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended Use Population: Initial Results from the Registrational PATHFINDER 2 Study
See Presentation
JCO Precision Oncology
Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes of Analysis
Read Full Article
Cancer Prevention Research
Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches
Read Full Article
American Association of Cancer Research (AACR) 2026
Association Between Emergency Department (ED) Involvement in Cancer Diagnosis and Survival Across Cancer Types in the Medicare Population